DexCom (NASDAQ:DXCM) Price Target Cut to $95.00 by Analysts at UBS Group

DexCom (NASDAQ:DXCM) had its price objective trimmed by UBS Group from $106.00 to $95.00 in a research note released on Monday,Benzinga reports. The firm currently has a buy rating on the medical device company’s stock.

Several other brokerages have also recently weighed in on DXCM. Piper Sandler set a $75.00 price objective on DexCom and gave the stock a “buy” rating in a report on Friday. Cowen reissued a “buy” rating on shares of DexCom in a report on Friday, October 24th. Barclays set a $80.00 price objective on DexCom and gave the stock an “equal weight” rating in a report on Monday. Mizuho boosted their price objective on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Finally, The Goldman Sachs Group dropped their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $89.33.

DexCom Stock Up 3.8%

Shares of NASDAQ DXCM opened at $60.43 on Monday. The company has a market cap of $23.70 billion, a price-to-earnings ratio of 41.97, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47. DexCom has a 12-month low of $56.44 and a 12-month high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm’s 50-day simple moving average is $70.63 and its 200 day simple moving average is $77.97.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. On average, research analysts expect that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Michael Jon Brown sold 500 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director directly owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 5,383 shares of company stock valued at $434,274. Insiders own 0.32% of the company’s stock.

Institutional Trading of DexCom

A number of large investors have recently bought and sold shares of DXCM. SWS Partners bought a new position in shares of DexCom during the 2nd quarter worth approximately $1,661,000. Baader Bank Aktiengesellschaft bought a new position in shares of DexCom during the 2nd quarter worth approximately $393,000. Jennison Associates LLC grew its stake in shares of DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after acquiring an additional 994,300 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of DexCom by 85.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock worth $105,469,000 after acquiring an additional 557,576 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. grew its stake in shares of DexCom by 4.9% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock worth $12,797,000 after acquiring an additional 6,800 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.